CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Lim, JSJ
Turner, NC
Yap, TA
Turner, NC
Yap, TA
Document Type
Journal Article
Date
2016-07
Date Accepted
2016-05-03
Abstract
Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast cancers as well as glioblastoma, melanoma, non-small cell lung cancer, colorectal cancer, and ovarian cancer. The development of abemaciclib and other CDK4/6 inhibitors should now be fully optimized through the use of novel predictive biomarkers of response and rational combinations. Cancer Discov; 6(7); 697-9. ©2016 AACRSee related article by Patnaik et al., p. 740.
Citation
Cancer discovery, 2016, 6 (7), pp. 697 - 699
Source Title
Publisher
ISSN
2159-8274
eISSN
2159-8290
Research Team
Molecular Oncology
Medicine Drug Development Unit (de Bono)
Medicine Drug Development Unit (de Bono)